Affordable Access

deepdyve-link
Publisher Website

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Authors
  • Barlow, Ashley1
  • Landolf, Kaitlin M.1
  • Barlow, Brooke2
  • Yeung, Siu Yan Amy1
  • Heavner, Jason J.3
  • Claassen, Cassidy W.4
  • Heavner, Mojdeh S.5
  • 1 University of Maryland Medical Center
  • 2 University of Kentucky Healthcare
  • 3 University of Maryland Baltimore Washington Medical Center
  • 4 University of Maryland School of Medicine
  • 5 University of Maryland School of Pharmacy
Type
Published Article
Journal
Pharmacotherapy
Publisher
John Wiley and Sons Inc.
Publication Date
May 06, 2020
Volume
40
Issue
5
Pages
416–437
Identifiers
DOI: 10.1002/phar.2398
PMID: 32259313
PMCID: PMC7262196
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID‐19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID‐19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS‐CoV‐2. Critically ill patients with COVID‐19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID‐19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.

Report this publication

Statistics

Seen <100 times